Detalhe da pesquisa
1.
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Blood
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518105
2.
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.
J Immunol
; 210(6): 753-763, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734626